Last reviewed · How we verify
AFFITOPE® PD01A
AFFITOPE® PD01A is designed to induce an immune response against alpha-synuclein, a protein implicated in Parkinson's disease.
AFFITOPE® PD01A is designed to induce an immune response against alpha-synuclein, a protein implicated in Parkinson's disease. Used for Parkinson's disease.
At a glance
| Generic name | AFFITOPE® PD01A |
|---|---|
| Sponsor | Affiris AG |
| Drug class | peptide |
| Target | alpha-synuclein |
| Modality | Biologic |
| Therapeutic area | Neurology |
| Phase | Phase 1 |
Mechanism of action
The drug works by stimulating the production of antibodies that specifically target and neutralize misfolded alpha-synuclein, potentially slowing the progression of the disease.
Approved indications
- Parkinson's disease
Common side effects
Key clinical trials
- Study Assessing Safety and Therapeutic Activity of AFFITOPE® PD01A and PD03A in Patients With Early MSA (PHASE1)
- Follow-up Study to Assess a Second Boost Immunization With AFFITOPE® PD01A With Regard to Safety and Clinical Activity (AFF008AA) (PHASE1)
- Study Assessing Tolerability and Safety and Exploring the Immunogenicity and Therapeutic Activity of AFFITOPE® PD01A in PD-GBA Patients (PHASE1)
- Follow-up Study to Assess One Boost Immunization With AFFITOPE® PD01A With Regard to Safety and Clinical Activity (PHASE1)
- AFF008E: Observational Phase 1b Follow-up Extension Study for Patients With Parkinson's Disease After Immunization With AFFITOPE® PD01A
- Tolerability and Safety of Subcutaneous Administration of Two Doses of AFFITOPE® PD01A in Early Parkinson's Disease (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AFFITOPE® PD01A CI brief — competitive landscape report
- AFFITOPE® PD01A updates RSS · CI watch RSS
- Affiris AG portfolio CI